ImPrecise Oversight? Cordis Monitoring Gaps Yield Second Warning Letter

J&J Cordis says it is developing more "robust" systems and processes for overseeing clinical studies in response to FDA's warning letter faulting the company for sponsor monitoring lapses in its SAPPHIRE trial